CABENUVA is the only complete, long-acting regimen for the treatment of HIV in suppressed patients.
Explore real-world data reinforcing efficacy through Month 61
See how patients, like yours, could benefit from a long-acting regimen
"It was the best change that I have had done so far. CABENUVA fits my lifestyle."
Felix—Patient Ambassador
CABENUVA is the only complete, long-acting regimen for the treatment of HIV in suppressed patients.
Efficacy reinforced by real-world data1
Could CABENUVA make an impact on your HIV patients?
"Unfortunately, sometimes having a bottle in your medicine cabinet, you know, it just gives you away."
Miranda—Patient Ambassador
Questions to ask your patients about taking daily oral therapy for HIV
How would you feel if you didn't have to take a daily oral therapy?
Would a long-acting regimen be a better fit for you?
Reference:
- Sinclair G, et al. Clinical outcomes at month 6 after initiation of cabotegravir and rilpivirine long-acting (CAB+RPV LA) in an observational real-world study (BEYOND). Poster presented at: IDWeek on HIV Treatment; October 11-15, 2023; Boston, MA.
PMUS-CBRWCNT240037